Top Page
Aerovate Therapeutics
(NASDAQ:AVTE)
Aerovate Therapeutics (AVTE) vs. SPDR S&P 500 ETF (SPY)
Aerovate Therapeutics Business Overview & Revenue Model
Aerovate Therapeutics Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 136.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 52.00K | 0.00 | -96.00K | -68.00K | -15.00K | -1.00K | EBIT |
| -88.40M | -74.60M | -81.41M | -53.24M | -23.02M | -8.89M | EBITDA |
| -88.32M | -74.31M | -81.31M | -53.17M | -23.01M | -8.89M | Net Income Common Stockholders |
| -85.24M | -69.63M | -75.52M | -51.51M | -22.96M | -9.04M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 99.33M | 78.62M | 122.44M | 129.22M | 167.38M | 4.57M | Total Assets |
| 106.82M | 80.33M | 127.42M | 135.30M | 175.36M | 4.71M | Total Debt |
| 774.00K | 417.00K | 675.00K | 1.09M | 574.00K | 0.00 | Net Debt |
| -8.35M | -33.33M | -22.82M | -21.31M | -53.62M | -4.57M | Total Liabilities |
| 15.92M | 3.90M | 17.96M | 8.56M | 2.94M | 18.06M | Stockholders Equity |
| 90.90M | 76.43M | 109.46M | 126.74M | 172.42M | -13.34M |
| Cash Flow | Free Cash Flow | ||||
| -65.77M | -71.20M | -56.92M | -39.32M | -27.58M | -7.86M | Operating Cash Flow |
| -65.71M | -71.20M | -56.78M | -39.12M | -27.40M | -7.86M | Investing Cash Flow |
| 32.48M | 56.03M | 11.88M | 6.93M | -113.43M | 0.00 | Financing Cash Flow |
| 120.09M | 25.43M | 46.00M | 396.00K | 190.46M | 8.92M |
Aerovate Therapeutics Technical Analysis
Aerovate Therapeutics Risk Analysis
Aerovate Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.24B | 3.27 | -45.39% | 2.80% | 16.77% | -0.07% | |
50 Neutral | $91.36M | ― | -71.46% | ― | ― | 17.20% | |
43 Neutral | $73.98M | ― | -456.32% | ― | ― | 0.13% | |
39 Underperform | $325.26M | ― | -59.01% | ― | ― | 44.04% | |
36 Underperform | $87.84M | ― | -76.21% | ― | ― | 23.55% | |
33 Underperform | $141.59M | 41.82 | 4.14% | ― | ― | 33.97% | |
30 Underperform | $119.50M | ― | -744.59% | ― | ― | 27.65% |
Aerovate Therapeutics Corporate Events
On April 28, 2025, Jade Biosciences, Inc. completed its merger with Aerovate Therapeutics, Inc., and will operate under the name Jade Biosciences, trading on Nasdaq under the ticker ‘JBIO’. The merger was accompanied by a successful private placement raising approximately $300 million, which includes the conversion of $95 million in previously issued convertible notes. This financial boost is expected to advance Jade’s portfolio of therapies for autoimmune diseases, with its lead candidate, JADE-001, anticipated to enter clinical trials in the latter half of 2025. The merger and financial developments are significant for Jade’s strategic positioning in the biopharma industry, potentially enhancing its capabilities to deliver innovative treatments for autoimmune conditions.
Spark’s Take on AVTE Stock
According to Spark, TipRanks’ AI Analyst, AVTE is a Underperform.
Aerovate Therapeutics receives a low stock score due to its poor financial performance characterized by zero revenue, significant losses, and negative cash flows. While technical indicators show some positive momentum, and recent corporate events offer potential improvements, the substantial financial risks and unfavorable valuation weigh heavily on the overall score.
To see Spark’s full report on AVTE stock, click here.
On April 29, 2025, Jade Biosciences released an updated corporate presentation highlighting their progress in developing therapies for autoimmune diseases. The presentation emphasized the potential of their lead candidate, JADE-001, as a best-in-class treatment for IgA nephropathy, a market estimated to be worth over $10 billion. The company has secured funding through 2027 and plans to initiate clinical trials for JADE-001 in the first half of 2026, aiming to address the unmet need for disease-modifying therapies in the IgAN market.
Spark’s Take on AVTE Stock
According to Spark, TipRanks’ AI Analyst, AVTE is a Underperform.
Aerovate Therapeutics faces major financial risks due to zero revenue, significant losses, and cash flow challenges. The technical outlook is neutral, while valuation remains poor. However, the merger with Jade Biosciences and special dividend announcement provide a positive note, slightly improving the stock’s speculative outlook.
To see Spark’s full report on AVTE stock, click here.
On April 16, 2025, Aerovate Therapeutics held a special meeting where stockholders approved a proposed merger with Jade Biosciences and all related proposals. This includes a reverse stock split and an increase in authorized shares, which are expected to impact the company’s stock structure and market presence. The merger aims to combine Aerovate’s focus on rare cardiopulmonary diseases with Jade’s expertise in autoimmune diseases, potentially enhancing their market positioning and offering new opportunities for stakeholders.
Spark’s Take on AVTE Stock
According to Spark, TipRanks’ AI Analyst, AVTE is a Underperform.
Aerovate Therapeutics’ stock score is primarily impacted by its poor financial performance, characterized by zero revenue, growing losses, and negative cash flows. While the technical outlook is neutral, the valuation remains challenging due to a negative P/E ratio. However, the recent corporate event involving a special dividend and potential merger offers a positive development that temporarily boosts the score.
To see Spark’s full report on AVTE stock, click here.
On April 9, 2025, Aerovate Therapeutics announced a special cash dividend of $69.6 million, or approximately $2.40 per share, in connection with its proposed merger with Jade Biosciences. The dividend is contingent upon the merger’s closing, expected around April 28, 2025, pending stockholder approval and satisfaction of all conditions. This announcement highlights Aerovate’s strategic move to merge with Jade, a company developing therapies for autoimmune diseases, potentially impacting stakeholders with changes in ownership and financial distributions.
Spark’s Take on AVTE Stock
According to Spark, TipRanks’ AI Analyst, AVTE is a Underperform.
Aerovate Therapeutics’ stock score is primarily impacted by its poor financial performance, characterized by zero revenue, growing losses, and negative cash flows. Technical indicators provide a neutral outlook, neither suggesting a strong buy nor sell signal. The valuation is unfavorable due to the negative P/E ratio, reflecting the company’s unprofitability. Overall, the stock is highly speculative with substantial financial risks.
To see Spark’s full report on AVTE stock, click here.
On April 7, 2025, Aerovate Therapeutics announced a proposed merger with Jade Biosciences, which includes a cash dividend for Aerovate’s pre-merger stockholders ranging from $67.6 to $69.6 million. The merger is subject to stockholder approval and other conditions, with the closing expected by April 30, 2025, potentially impacting the company’s financial positioning and stakeholder interests.
Spark’s Take on AVTE Stock
According to Spark, TipRanks’ AI Analyst, AVTE is a Underperform.
Aerovate Therapeutics’ stock score is primarily impacted by its poor financial performance, characterized by zero revenue, growing losses, and negative cash flows. Technical indicators provide a neutral outlook, neither suggesting a strong buy nor sell signal. The valuation is unfavorable due to the negative P/E ratio, reflecting the company’s unprofitability. Overall, the stock is highly speculative with substantial financial risks.
To see Spark’s full report on AVTE stock, click here.